Caribou Biosciences shares rose after its CAR-T therapies showed high response rates and durable remissions in lymphoma and myeloma trials.

A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.

Understanding how cells turn genes on and off is one of biology's most enduring mysteries. Now, a new technology developed by ...

Pairwise has licensed its Fulcrum® gene editing platform to the International Rice Research Institute (IRRI), a non-profit agricultural research organization. The agreement will enable IRRI to apply ...

Caribou Biosciences said its off-the-shelf CAR-T therapy induced complete and durable remissions in patients with advanced ...